<?xml version='1.0' encoding='utf-8'?>
<document id="32052379"><sentence text="Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies." /><sentence text="Understanding transporter-mediated drug-drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies" /><sentence text=" P-glycoprotein (P-gp) is an efflux transporter that influences the pharmacokinetics (PK) of various compounds" /><sentence text=" Assessing transporter induction in vitro is challenging and is not always predictive of in vivo effects, and hence there is a need to consider clinical DDI studies; however, there is no clear guidance on when clinical evaluation of transporter induction is required" /><sentence text=" Furthermore, there is no proposed list of index transporter inducers to be used in clinical studies" /><sentence text=" This review evaluated DDI studies with known P-gp inducers to better understand the mechanism and site of P-gp induction, as well as the magnitude of induction effect on the exposure of P-gp substrates" /><sentence text=" Our review indicates that P-gp and cytochrome P450 (CYP450) enzymes are co-regulated via the pregnane xenobiotic receptor (PXR) and the constitutive androstane receptor (CAR)"><entity charOffset="150-160" id="DDI-PubMed.32052379.s7.e0" text="androstane" /></sentence><sentence text=" The magnitude of the decrease in substrate drug exposure by P-gp induction is generally less than that of CYP3A" /><sentence text=" Most P-gp inducers reduced total bioavailability with a minor impact on renal clearance, despite known expression of P-gp at the apical membrane of the kidney proximal tubules" /><sentence text=" Rifampin is the most potent P-gp inducer, resulting in an average reduction in substrate exposure ranging between 20 and 67%"><entity charOffset="1-9" id="DDI-PubMed.32052379.s10.e0" text="Rifampin" /></sentence><sentence text=" For other inducers, the reduction in P-gp substrate exposure ranged from 12 to 42%" /><sentence text=" A lower reduction in exposure of the P-gp substrate was observed with a lower dose of the inducer and/or if the administration of the inducer and substrate was simultaneous, i" /><sentence text="e" /><sentence text=" not staggered" /><sentence text=" These findings suggest that clinical evaluation of the impact of P-gp inducers on the PK of investigational agents that are substrates for P-gp might be warranted only for compounds with a relatively steep exposure-efficacy relationship" /><sentence text="" /></document>